Join Karra Harrington, PhD, Principal Scientist at Cogstate, for a webinar exploring how digital cognitive assessments can support case finding and participant enrichment in preclinical and early symptomatic AD trials. Register now: https://t.co/vKyAqJkoDu
As Alzheimer’s trials move earlier in the disease continuum, measuring treatment benefit becomes increasingly complex. Hear from Ed Bartolic, who joined our partners at Clinical ink on bringing the science and execution together: https://t.co/rsGeLsJf75
Digital PACC assessments developed and validated by Cogstate reduce burden on raters, while also reducing participant and site burden and supporting valid, reliable measurement across diverse populations.
Explore these innovations in our whitepaper. https://t.co/FrJjN1Kce2
Cogstate researchers and collaborators will share work at #CTAD26 spanning AD biomarkers and cognitive change, early detection, digital measures and assessment performance. Explore our presentations, and connect with us in Boston: https://t.co/rG0RFWF3S3
CTAD 2026 brings important conversations on the future of Alzheimer’s disease research, from new trial readouts to advances in digital measures, biomarkers and diagnostics. Connect with us in Boston: https://t.co/rG0RFWF3S3
New data from Cogstate scientist Karra Harrington shows strong concordance between Cogstate’s self-administered LILA app and telehealth-administered assessments—supporting a more flexible, accessible approach to cognitive screening. Review the poster: https://t.co/909c6BjLmV
New research explores the potential of digital cognitive assessments to detect subtle, domain-specific changes associated with early Alzheimer’s disease pathology. To view this data and other Cogstate posters presented at AAIC 2026, visit https://t.co/SzPcDgcoJI
Psychedelic trials present unique challenges for endpoint quality. Central Rating helps sponsors support blinding, reduce variability, and strengthen confidence: in clinician-rated outcomes such as MADRS. https://t.co/kcKbVAOIu0
For MADRS and HAM-D assessments, seemingly small differences in their administration can affect endpoint data quality. We revisit 3 common rater errors and practical considerations for strengthening rater training and calibration.
Read the blog: https://t.co/wVIALMs5MV
Join Join Luka Lucić, PhD, and Svenja Wacker, PhD, for an upcoming webinar exploring a signal intelligence framework for distinguishing meaningful clinical improvement from measurement noise and other sources of pseudo-improvement. Register now: https://t.co/5pDug8u4sb
We’re honored to announce that Cogstate has been selected to support cognitive measurement in the XPRIZE Healthspan competition, a 7-year, $101 million global competition designed to revolutionize human aging.
Read the announcement: https://t.co/TJwLN578Yd
Our latest blog explores why an end-to-end strategy is becoming increasingly important for rare disease research and how integrated approaches to rater training, eCOA design, and central monitoring can help improve confidence in trial outcomes.
Read more: https://t.co/nPnHPrFn4S
Can lifestyle interventions meaningfully slow cognitive decline? Results from the US POINTER trial suggest they can. Cogstate is proud to support research in this area through validated cognitive assessments. Read the study: https://t.co/wlczJx6hXI
The countdown to #AAIC26 is on! In just a few weeks, the Cogstate team will join the global Alzheimer's disease research community in London. Explore Cogstate's full list of AAIC 2026 presentations: https://t.co/g67T8oQoCr
It's National Work from Home Day—but at Cogstate, that’s every day. As a virtual‑first organization, flexibility is just one part of how we enable our teams to do their best work. Interested in joining us? Explore opportunities on our careers page: https://t.co/tA3oHs6dzj
Our US offices are closed today in observance of Juneteenth, a day that marks a time when freedom was delayed, and a reminder that inequity doesn't end with declaration. It’s a time to reflect on progress and consider how each of us contributes to a more equitable future.
London, here we come! We're thrilled to join the global Alzheimer's disease community at #AAIC26 and discuss what's next for AD research. Schedule a meeting 👉 https://t.co/g67T8oQoCr
Recent research on NGLY1 Deficiency Disorder highlights how longitudinal cognitive and functional data can inform endpoint selection, expected trajectories, and meaningful change (Morrison et al., Human Molecular Genetics). Read the publication: https://t.co/GJxQjHOkOL
A new study by Prof. Paul Maruff and co-authors shows that remote, unsupervised cognitive testing using the Cogstate Brief Battery delivers results comparable to in-clinic assessments—and remains sensitive to early cognitive decline. Read the publication: https://t.co/0XsyGTpHCR
Recent work from Rachel Buckley and team examining p‑Tau217, tau aggregation, and cognitive decline in preclinical AD suggests that disease trajectories—and their cognitive expression—can differ by sex. Read the publication: https://t.co/gtIcjUpmHA